Craig-Hallum analyst Albert Lowe initiated coverage of Opus Genetics (IRD) with a Buy rating and $6 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics announces data from patient in Phase 1/2 trial of OPGx-LCA5
- Opus Genetics urges stockholders to vote for company’s nine board nominees
- Opus Genetics Terminates Purchase Agreement with Lincoln Park
- Opus Genetics price target lowered to $8 from $9 at JonesResearch
- Opus Genetics: Strategic Advances in AAV-Based Gene Therapies and Key Catalysts for Growth